XML 56 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Segments of Business and Geographic Areas (Tables)
 9 Months Ended
Sep. 27, 2015
Segment Reporting [Abstract]  
Sales By Segment Of Business
 
 
Fiscal Third Quarters Ended
(Dollars in Millions)
 
September 27,
2015
 
September 28,
2014
 
Percent
Change
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
United States
 
$
1,277

 
1,173

 
8.9
 %
International
 
2,037

 
2,416

 
(15.7
)
Total
 
3,314

 
3,589

 
(7.7
)
Pharmaceutical
 
 
 
 
 
 
United States
 
4,509

 
4,723

 
(4.5
)
International
 
3,185

 
3,584

 
(11.1
)
Total
 
7,694

 
8,307

 
(7.4
)
Medical Devices
 
 
 
 
 
 
United States
 
3,005

 
2,946

 
2.0

International
 
3,089

 
3,625

 
(14.8
)
Total
 
6,094

 
6,571

 
(7.3
)
Worldwide
 
 
 
 
 
 
United States
 
8,791

 
8,842

 
(0.6
)
International
 
8,311

 
9,625

 
(13.7
)
Total
 
$
17,102

 
18,467

 
(7.4
)%

 
 
 
 
 
 
 
 
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 27,
2015
 
September 28,
2014
 
Percent
Change
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
United States
 
$
3,991

 
3,802

 
5.0
 %
International
 
6,196

 
7,088

 
(12.6
)
Total
 
10,187

 
10,890

 
(6.5
)
Pharmaceutical
 
 
 
 
 
 
United States
 
13,423

 
13,076

 
2.7

International
 
9,943

 
11,238

 
(11.5
)
Total
 
23,366

 
24,314

 
(3.9
)
Medical Devices
 
 
 
 
 
 
United States
 
8,980

 
9,300

 
(3.4
)
International
 
9,730

 
11,573

 
(15.9
)
Total
 
18,710

 
20,873

 
(10.4
)
Worldwide
 
 
 
 
 
 
United States
 
26,394

 
26,178

 
0.8

International
 
25,869

 
29,899

 
(13.5
)
Total
 
$
52,263

 
56,077

 
(6.8
)%
Operating profit by segment of business
 
 
Fiscal Third Quarters Ended
(Dollars in Millions)
 
September 27,
2015
 
September 28,
2014
 
Percent
Change
Consumer (1)
 
$
811

 
407

 
99.3
 %
Pharmaceutical(2)
 
2,732

 
3,247

 
(15.9
)
Medical Devices(3)
 
835

 
3,399

 
(75.4
)
Segments operating profit
 
4,378

 
7,053

 
(37.9
)
Less: Expense not allocated to segments (4)
 
256

 
243

 
 
Worldwide income before taxes
 
$
4,122

 
6,810

 
(39.5
)%

 
 
 
 
 
 
 
 
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 27, 2015
 
September 28, 2014
 
Percent
Change
Consumer (1)
 
$
1,772

 
1,588

 
11.6
 %
Pharmaceutical(2)
 
9,816

 
9,921

 
(1.1
)
Medical Devices(3)
 
4,640

 
7,069

 
(34.4
)
Segments operating profit
 
16,228

 
18,578

 
(12.6
)
Less: Expense not allocated to segments (4)
 
790

 
718

 
 
Worldwide income before taxes
 
$
15,438

 
17,860

 
(13.6
)%

(1) Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y® brand recorded in the fiscal nine months of 2014.

(2) Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014.
(3) Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million, Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASRTM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million, Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal nine months of 2014.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
 
 
Fiscal Third Quarters Ended
(Dollars in Millions)
 
September 27, 2015
 
September 28, 2014
 
Percent
Change
United States
 
$
8,791

 
8,842

 
(0.6
)%
Europe
 
3,802

 
4,446

 
(14.5
)
Western Hemisphere, excluding U.S.
 
1,463

 
1,820

 
(19.6
)
Asia-Pacific, Africa
 
3,046

 
3,359

 
(9.3
)
Total
 
$
17,102

 
18,467

 
(7.4
)%

 
 
 
 
 
 
 
 
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 27, 2015
 
September 28, 2014
 
Percent
Change
United States
 
$
26,394

 
26,178

 
0.8
 %
Europe
 
11,993

 
14,387

 
(16.6
)
Western Hemisphere, excluding U.S.
 
4,603

 
5,378

 
(14.4
)
Asia-Pacific, Africa
 
9,273

 
10,134

 
(8.5
)
Total
 
$
52,263

 
56,077

 
(6.8
)%